MicroRNA ‐324‐3p inhibits osteosarcoma progression by suppressing PGAM1 ‐mediated aerobic glycolysis
Cancer Science · 2023
DOI: 10.1111/cas.15779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Yiping Weng und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Bone Neoplasms, MicroRNAs, Osteosarcoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changzhou Medical Center of Nanjing Medical University, Changzhou Science and Technology Bureau, the Natural Science Foundation of Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Osteosarcoma (OS) is the most common primary malignant neoplasm of the bone. Recent studies have indicated that the inhibitory effects of microRNA (miR)‐324‐3p could affect the development of numerous cancers. However, its biological roles and underlying mechanisms in OS progression remain unexplored. In this study, miR‐324‐3p expression was markedly reduced in OS cell lines and tissues. Functionally, miR‐324‐3p overexpression suppressed OS progression and was involved in the Warburg effect. Mechanistically, miR‐324‐3p negatively regulated phosphoglycerate mutase 1 (PGAM1) expression by targeting its 3′‐UTR. Moreover, high expression of PGAM1 promoted OS progression and aerobic glycolysis, which were associated with inferior overall survival in patients with OS. Notably, the tumor suppressor functions of miR‐324‐3p were partially recovered by PGAM1 overexpression. In summary, the miR‐324‐3p/PGAM1 axis plays an important role in regulating OS progression by controlling the Warburg effect. Our results provide mechanistic insights into the function of miR‐324‐3p in glucose metabolism and subsequently on the progression of OS. Targeting the miR‐324‐3p/PGAM1 axis could be a promising molecular strategy for the treatment of OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
- Department of Orthopedics, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.
- Graduate School, Dalian Medical University, Dalian, China.
ORCID-Profile: Yifei Shen
Förderung
- Changzhou Medical Center of Nanjing Medical University
- Changzhou Science and Technology Bureau
- the Natural Science Foundation of Xinjiang Uygur Autonomous Region
Zitieren
APA
Weng, Y., Duan, W., Yu, X., Wu, F., Yang, D., Jiang, Y., Wu, J., Wang, M., Wang, X., Shen, Y., Zhang, Y., & Xu, H. (2023). MicroRNA ‐324‐3p inhibits osteosarcoma progression by suppressing PGAM1 ‐mediated aerobic glycolysis. Cancer Science. https://doi.org/10.1111/cas.15779
Vancouver
Weng Y, Duan W, Yu X, Wu F, Yang D, Jiang Y, et al. MicroRNA ‐324‐3p inhibits osteosarcoma progression by suppressing PGAM1 ‐mediated aerobic glycolysis. Cancer Science. 2023. doi:10.1111/cas.15779
BibTeX
@article{Weng2023,
author = {Weng, Yiping and Duan, Weihao and Yu, Xuecheng and Wu, Furen and Yang, Daibin and Jiang, Yuqing and Wu, Jingbin and Wang, Muyi and Wang, Xin and Shen, Yifei and Zhang, Yunkun and Xu, Hua},
title = {MicroRNA ‐324‐3p inhibits osteosarcoma progression by suppressing PGAM1 ‐mediated aerobic glycolysis},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15779}
}
EUVIMED